The Efficacy and Safety of OROSARTAN® Versus CODIOVAN® in Patients With Essential Hypertension Uncontrolled With Monotherapy

• Status: Completed
• Trial end date: 2016-09-08
• Target enrollment: 0
• Participant gender: All

Summary

A multi-center, randomized, double-blind, phase IV clinical trial to compare the efficacy and safety of OROSARTAN® tablet 5/160mg versus CODIOVAN® tablet 160/12.5mg in patients with essential hypertension uncontrolled with valsartan 160mg monotherapy

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dong-A ST Co., Ltd.
• Treatments: Amlodipine; Hydrochlorothiazide; Valsartan

Criteria

Inclusion Criteria:

• 19 aged or over

• A patient who was diagnosed with essential hypertension at screening(Visit 1)

• A patient understood objective of this clinical trial and gave their written informed consent voluntarily

Exclusion Criteria:

• A patient with severe hypertension(MSSBP≥200mmHg or MSDBP≥120mmHg) at Visit 1

• A subject with difference(as MSSBP≥20mmHg or MSDBP≥10mmHg) in blood pressure between right and left arm at screening evaluation

• Medical history or evidence of a secondary form of hypertension

• A subject with history of hypersensitivity to CCB(Calcium Channel Blocker), ARB(Angiotensin II Receptor Blocker) or sulfonamide